AKT1 and medullary thyroid gland carcinoma: Phospho-Thr308 AKT was reduced in tumors from Vandetanib, Nintedanib, and Nintedanib + Romidepsin treated mice, but not in mice treated with Romidepsin alone in comparison with vehicle-treated MTC mice.